Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PBM, Chain Drug Summer Lobbying Focuses On Mail-Order Rx In Medicare

Executive Summary

Chain drug stores and PBMs are trying to shape the role of retail and mail-order pharmacy in a Medicare prescription drug benefit through "grassroots" lobbying campaigns during Congress' August recess

You may also be interested in...

Medicare Rx Discount Card Rebate Pass-Through Opposed By White House

The White House is opposed to requiring Medicare prescription drug discount card sponsors to pass through all drug rebates and discounts to the consumer

Medicare PBM Restrictions Would Lead To Higher Premiums, CBO Says

The PBM "transparency" provision in the Senate's Medicare prescription drug bill would lead to higher monthly premiums and higher beneficiary cost-sharing, the Congressional Budget Office said

PBM Fees Under Medicare Would Be Reported To DoJ, HHS In Senate Bill

PBMs administering Medicare drug plans would be required to report all payments received from drug manufacturers to the Department of Justice and the HHS Inspector General under the Senate's Medicare legislation

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts